Previous 10 | Next 10 |
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
As expected, the European Commission approves the use of Johnson & Johnson ( JNJ -0.2% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide) and dexamethasone, for the treatment of adults with newly diagnosed multiple myeloma who are ineligi...
Genmab A/S (NASDAQ: GMAB ): Q3 GAAP EPS of DKK8.28. More news on: Genmab A/S, Genmab A/S, Genmab A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...
Creating a list of companies that will make my elite list of 2029 investments that will have increased in value by a factor of 10 or more is a major challenge for more than one reason. As I stated in my previous article, in our fast moving world, industries unknown today may be household names...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...
AbbVie (NYSE: ABBV ) upgraded to Buy with a $79 (14% upside) price target at UBS. Shares up 2% premarket. More news on: AbbVie Inc., Seattle Genetics, Inc., Varian Medical Systems, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Genmab GMAB has entered into a strategic collaboration agreement with Tempus, to research and develop novel targets. More news on: Genmab A/S, Genmab A/S, Read more ...
Sophisticated pharma investors will need to review the IGM Biosciences ( IGMS )' preclinical data. Janus Capital Management acquired shares, and the company holds a significant amount of cash. It means that preclinical research impressed institutional investors and may impress others. Having s...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...